Manuka Health Wednesday 22 February 2012, 8:52AM
Waikato-based company Manuka Health has signed an agreement with
Japanese company CycloChem Bio Limited to import new cyclodextrin
technology into New Zealand.
CycloChem Bio has developed a manufacturing process in which
cyclodextrins - beneficial compounds derived from plants - can be
used to encapsulate bioactives from natural products such as manuka
Together with scientists at the Kobe Medical School, CycloChem Bio
discovered that cyclodextrins (oligosaccharide molecules) - can act
as bioactive boosters when combined with the bioactives in manuka
Their studies show that MGO™ Manuka Honey, taken as a supplement,
has ten times more potency against bacteria such as Streptococcus
pyogenes and Helicobacter pylori, responsible for throat and
Manuka Health's chief executive officer Mr Kerry Paul says under
the agreement his company can manufacture encapsulated manuka honey
and other bioactives in a range of delivery systems such as a
tablet, capsule, ointment and spray, using cyclodextrins
Manuka Health has trademarked the new generation products as
"Importing technologies which enable cyclodextrins to be combined
with natural products adds value to the manuka honey industry and
improves the efficacy of bioactive products," says Mr Paul.
"Cyclodextrins carry beneficial, natural bioactives through the
digestive tract, making them more effective, soluble, stable and
palatable. Presently, swallowing a supplement doesn't always
guarantee your body will get the benefits. Our new generation of
products should ensure people are not wasting their money."
Initially, the company will manufacture cyclodextrins at Auckland's
Mangere "Food Bowl" facility while planning gets underway for a
new, state-of-the-art $8 million extraction and processing plant at
Te Awamutu. Construction is expected to begin next year.
Manuka Health recently purchased a 1.3 hectare site in Te Awamutu
where it will consolidate the company's current operations - now
spread over four sites - and provide the capacity to develop new
generation bioactive products.
The company, which is rapidly becoming a leader in technology
transfer, last week received a New Zealand Trade and Enterprise
national growth fund grant to assist in marketing the new
generation of manuka honey products. The grant, aimed at small to
medium-sized businesses, will match Manuka Health's marketing
budget for the new products dollar for dollar.
Manuka Health was established in 2006 following discovery by
Professor Thomas Henle, Technical University of Dresden, of the
compound, methylglyoxal, in manuka honey responsible for its
Mr Paul says this discovery provided the platform for his company's
developments, but ongoing research into the rich field of
bioactives is needed to further grow New Zealand's unique
capability in natural healthcare and wellness products.
The company, which already has a research partnership with the
Technical University of Dresden, is now looking to build new
research collaborations between Dresden and New Zealand research
Since its formation six years ago, Manuka Health has achieved
growth of $15 to $20 million turnover a year and now exports to
more than 45 countries.
A finalist in the 2010 New Zealand International Business Awards in
the "Best Business Operating Internationally" category, Manuka
Health is the first company in the world to introduce a robust,
scientific measurement for rating methylglyoxal levels in manuka